HCW Biologics Inc. (HCWB)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 16K | 27K | 6.5M | 136K |
| Gross Profit | 3K | 5K | 6.5M | (94K) |
| Operating Income | (3.3M) | (2.9M) | 3.3M | (3.2M) |
| Net Income | (4.6M) | 719K | 3.5M | (5.2M) |
| Diluted EPS | $-2.02 | $-1.02 | $0.37 | $-11.58 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 6.7M | 2.8M | 2.6M | 54K |
| Gross Profit | 2.6M | 560K | 959K | 11K |
| Operating Income | (15.1M) | (25.7M) | (27.6M) | (11.3M) |
| Net Income | (14.9M) | (25.0M) | (30.0M) | (8.0M) |
| Diluted EPS | $-16.80 | $-28.00 | $-30.80 | $-10.63 |